LENZ Therapeutics (LENZ) to Announce Quarterly Earnings on Wednesday

LENZ Therapeutics (NASDAQ:LENZ) is projected to post its Q2 2026 results before the market opens on Wednesday, July 29th. Analysts expect LENZ Therapeutics to announce earnings of ($1.0505) per share and revenue of $2.3770 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:00 PM ET.

LENZ Therapeutics (NASDAQ:LENZ) last released its quarterly earnings results on Monday, May 11th. The company reported ($1.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.10) by ($0.22). The firm had revenue of $1.90 million for the quarter, compared to analyst estimates of $1.76 million. LENZ Therapeutics had a negative net margin of 519.30% and a negative return on equity of 46.82%. On average, analysts expect LENZ Therapeutics to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

LENZ Therapeutics Stock Performance

Shares of NASDAQ:LENZ opened at $5.48 on Monday. The firm has a 50 day simple moving average of $6.26 and a 200 day simple moving average of $10.27. LENZ Therapeutics has a 52 week low of $4.68 and a 52 week high of $50.40. The company has a market cap of $171.80 million, a PE ratio of -1.52 and a beta of 0.62.

Analyst Ratings Changes

Several brokerages have issued reports on LENZ. Citigroup cut their target price on shares of LENZ Therapeutics from $26.00 to $20.00 and set a “buy” rating on the stock in a research note on Wednesday, May 13th. Piper Sandler cut LENZ Therapeutics from an “overweight” rating to a “neutral” rating and decreased their target price for the stock from $39.00 to $12.00 in a research report on Tuesday, May 12th. HC Wainwright reiterated a “buy” rating on shares of LENZ Therapeutics in a report on Tuesday, July 7th. Zacks Research lowered LENZ Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Wednesday, July 15th. Finally, Weiss Ratings raised LENZ Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, June 17th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $29.80.

Institutional Trading of LENZ Therapeutics

A number of institutional investors have recently bought and sold shares of the company. Virtu Financial LLC purchased a new position in LENZ Therapeutics in the fourth quarter valued at about $198,000. XTX Topco Ltd purchased a new stake in shares of LENZ Therapeutics during the 4th quarter worth about $1,373,000. VARCOV Co. purchased a new stake in shares of LENZ Therapeutics during the 4th quarter worth about $1,261,000. Vestal Point Capital LP acquired a new stake in shares of LENZ Therapeutics during the 4th quarter valued at about $4,400,000. Finally, Virtus Investment Advisers LLC lifted its holdings in shares of LENZ Therapeutics by 879.3% during the 4th quarter. Virtus Investment Advisers LLC now owns 37,674 shares of the company’s stock valued at $603,000 after buying an additional 33,827 shares during the last quarter. Institutional investors and hedge funds own 54.32% of the company’s stock.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.